Governor Tim Walz says the earliest he can call a special session will be the middle of next week. The budget deals in a few ...

bluebird bio faces imminent bankruptcy unless a deal closes; current offer is $5 cash or $3 plus a low-value CVR. A rival ...

WORTHINGTON — Representatives from the Worthington Hockey Association discussed fundraising efforts for a new ice arena with ...

Along with its Q4 2024 financials on Thursday, antiviral developer Arbutus Biopharma (NASDAQ:ABUS) announced plans to reduce its workforce by 57% as part of a broader restructuring program, which also ...

Christopher DeMuth is a distinguished fellow in American thought at the Heritage Foundation. Michael S. Greve is a professor of law at the Antonin Scalia Law School.

Demuth and other Republicans at the Capitol ... Walz’s chief of staff, Chris Schmitter, and deputy chief of staff on legislative affairs, Leah Montgomery, maintain frequent contact with ...

Chris DeMuth, Jr. shares some of his current top picks. Arbutus Biopharma is a promising investment due to its potential litigation value from IP claims against Pfizer and Moderna related to COVID ...

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor.

Minneapolis saw a rise in homicides in 2024 while the nation’s homicide rate declined by 16%, reports Minnesota Reformer’s Christopher ... Lisa Demuth, who will lead the GOP caucus in what ...

Chris DeMuth Jr. shares why demutualization presents consistent opportunities, with many banks selling at significant premiums within 3-5 years post-demutualization. Credit unions, being cash-rich ...